Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared an article by Claire Roddie et al. published in ASH on X:
”Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
- CAR T-cell Rx post allo-HCT can be challenging due to lymphopenia/T-cell depletion.
- Allogeniec CAR T-cell demonstrated expansion/persistence when preceded by lymphodepletion, minimal GVHD.
- OS at 12 mo (83%) with CAR+LD vs (29%) with CAR no LD.”
Title: Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Authors: Claire Roddie, Juliana Dias, Maeve A. O’Reilly, Mahnaz Abbasian, Amaia Cadinanos-Garai, Ketki Vispute, Leticia Bosshard-Carter, Marina Mitsikakou, Eftychia Charalambous, Vedika Mehra, Harriet Roddy, Gordon Weng-Kit Cheung, John A. Hartley, Nasir Mahmoud, Leah Ensell, Yashma Patel, Maria A. V. Marzolini, Farzin Farzaneh, Lauren Nickolay, Nourredine Himoudi, Farhatullah Syed, Bilyana Popova, Sevasti Galani, Alexander Day, Mark W. Lowdell, Karl S. Peggs
You can read the Full Article.
More posts featuring Talha Badar.